The novel coronavirus pandemic has upended our lives, creating a far-from-normal “new normal.” And it has also given rise to countless collaborations between and among universities, hospitals, medical centers, pharma companies and others to pool their talent and resources to discover, test, manufacture and distribute diagnostics, treatments, vaccines, personal protective equipment and other resources needed to fight the pandemic. Antitrust law poses no risk to these collaborations, so long as they remain focused on their core missions. But at the same time, antitrust law recognizes that in cooperating and exchanging information and insights for those missions there is the potential for “spill-over effects” that can create antitrust risk. The trick is to know where that dividing line is and to avoid crossing over it.
Examining Antitrust Guidance on Cooperation in Fighting COVID-19
No Comments
Business
- Innovation Alliance Urges Biden Administration to Support Patent Rights
- Trade and Commerce in West Africa and How it Influences IP Rights
- Supreme Court Ponders Proper Application of the Computer Fraud and Abuse Act
- How Patents Helped Sprout the World’s First Plantable Pencil
- Patent Filings Roundup: Battle-Tested Off-Roading Patent Asserted; Jack Henry Battered Again
Recent Posts
- Other Barks & Bites for Friday, January 22: Iancu and Peter Step Down from USPTO, CJEU Asked Whether Preliminary Injunction Standard Burdens Patent Owners, SCOTUS Denial Leaves Invalidation of Idenix Genus Patent Claims Untouched
- US Inventor Backs SCOTUS Petition to Clarify Claim Construction Principles
- Iancu Says Goodbye, Urges Commitment to ‘American Innovation Renaissance’
- Biden’s Opportunity to Protect American Innovation
- Washington Insiders Say Farewell to 2020 and Look Ahead to 2021